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Abstract To develop a European guideline on pharma-
cologic treatment of Tourette syndrome (TS) the available
literature was thoroughly screened and extensively dis-
cussed by a working group of the European Society for the
Study of Tourette syndrome (ESSTS). Although there are
many more studies on pharmacotherapy of TS than on
behavioral treatment options, only a limited number of
studies meets rigorous quality criteria. Therefore, we have
devised a two-stage approach. First, we present the highest
level of evidence by reporting the ﬁndings of existing
Cochrane reviews in this ﬁeld. Subsequently, we provide
the ﬁrst comprehensive overview of all reports on phar-
macological treatment options for TS through a MEDLINE,
PubMed, and EMBASE search for all studies that document
the effect of pharmacological treatment of TS and other tic
disorders between 1970 and November 2010. We present a
summary of the current consensus on pharmacological
treatment options for TS in Europe to guide the clinician in
daily practice. This summary is, however, rather a status
quo of a clinically helpful but merely low evidence
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Introduction
Tic disorders including Tourette syndrome (TS) are neu-
ropsychiatric disorders with higher prevalence rates than
previously thought, of up to 3–4% for chronic motor or
vocal tic disorders and 1% (range 0.05–3%) for TS [196],
which is the combination of chronic motor and vocal tics
persisting for at least one year. The typical age of onset of
tics is between 4 and 8, and tics reach their peak severity
early in the second decade of life often followed by a time
of remission of tics [44, 228]. Overall, TS has often a
favorable prognosis: follow-up studies of TS suggest that
approximately one third of children with TS are essentially
symptom-free as adults; another third will have mild tics
that do not require clinical attention [22]. Adults who still
have symptoms severe enough to come to clinical attention
are therefore unusual representatives of all subjects who
have received a diagnosis of TS.
Diagnosing a tic disorder including the differentiation of
tics from other movement disorders is usually a simple task
(see Cath et al. this issue). It is, however, essential to detect
coexisting conditions and to assess the contribution of the
tics and/or coexisting conditions to the patient’s psycho-
social impairment in everyday life, because the coexisting
conditions often are closely related to the latter, yet they do
not explain fully the level of function [95].
Indications for treatment of TS
We use the term TS in these guidelines, although infor-
mation also applies to other chronic tic disorders. Decisions
about treatment of TS must be based on a thorough and
broad diagnostic process. It is difﬁcult to give guidelines
with regard to indications for pharmacological treatment of
TS, ﬁrst, because persons with TS have a high interindi-
vidual variability of symptoms, secondly, due to the tem-
poral ﬂuctuations of tics and thirdly, because coexisting
conditions may interfere with the treatment effects for the
tics. Moreover, subjective impairment does not necessarily
equate objective tic severity: some individuals with rela-
tively severe tics experience only mild impairment,
whereas in other cases mild tics may be associated with
signiﬁcant suffering [225].
Many children and adolescents with TS do not require
treatment for their tics, since their tics do not interfere with
daily life or recreational activities. Indeed, only a minority of
individualswithticsseekmedicaladvice[194].Manypatients
do well with a watchand wait strategy after psychoeducation
and reassurance. Psychoeducation in TS has the aim to
improve the tolerance for symptoms and to support stress
reduction. Psychoeducation includes information about the
long- and short-term variability of tics, about the natural
course and about possible coexisting problems. A watch and
wait strategy is also justiﬁed by the fact that we still lack
evidence of the effect that pharmacological treatment of TS
hasonthenaturallong-termcourseandhenceontheprognosis
of the disorder and how this kind of treatment may inﬂuence
thenaturalcourseofbraindevelopment.Allpharmacological
treatment options are therefore mere symptomatic treatment
that alleviate, but do not cure the tics [87].
Non-pharmacologic and/or pharmacologic interventions
should be considered in addition to psychoeducation for
persons with clear impairment associated with the tics,
either at ﬁrst referral or later, due to exacerbation of
symptoms. A number of reviews (e.g. [87, 246]) have
published lists of indications for pharmacological treatment
of tics, but none of them reﬂects the consensus of experts.
We recommend that treatment of tics should be considered
in the following circumstances, especially when persisting
for some days.
Tics cause subjective discomfort (e.g. pain or injury)
Pain in TS may arise from the actual performance of fre-
quent or intense tics causing discomfort by sudden or
repeated extreme exertion (e.g. with head or neck). This
kind of pain is usually musculoskeletal, although rare
examples of neuropathic pain may occur. Tics can, in rare
cases, cause injuries [125], e.g., a fracture line of both
peroneal bones in a 13-year-old boy with TS and obses-
sive–compulsive disorder (OCD) admitted to hospital
because of pain in his legs [80]. Striking or being struck by
a moving body part involved in large amplitude tics may
also cause pain and is sometimes difﬁcult to distinguish
from deliberate self-injury. Additionally, some patients
obtain relief from tics while experiencing pain, to such an
extent that they will deliberately provoke pain to obtain
beneﬁt [193]. A smaller number of patients complain of
pain associated with the irresistible urge to tic or with
aggravating premonitory urges during voluntary efforts to
suppress their tics. Some patients report that tics worsen
their headaches or migraines. In those cases, tic-suppres-
sive medication could be helpful in reducing the use of pain
medication and should be considered.
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(e.g., social isolation or bullying)
Persistent complex motor tics and loud phonic tics can
cause social problems. Tics may cause isolation, bullying,
or social stigmatization; loud phonic tics may result in the
child being put out of the classroom. In such cases, a tic
reduction, in addition to psychoeducation for the teacher,
can be socially very helpful.
However, tics do not lead to social impairments in all
cases. Therefore, the issue of social problems needs to be
assessed carefully. For example, parents of young children
are often exceedingly worried about social problems,
whereas adolescents sometimes overestimate the social
consequences of their tics and children in the ﬁrst ele-
mentary grades are often tolerant of tics. Coexisting con-
ditions are more often the cause than tics, if a primary
school child gets socially isolated by peers [54]. In higher
school classes, bullying and social stigmatization due to
tics becomes more common. After proper psychoeducation,
many children and adolescents will accept their tic symp-
toms and await the natural remission; however, sometimes
medication is indicated to avoid social stigmatization.
Tics cause social and emotional problems
for the patient (e.g., reactive depressive symptoms)
Inadditiontotheaforementioned,sustainedsocialproblems,
consequent to negative reactions of the social environment,
some patients develop depressive and anxious symptoms,
low self-esteem, and/or social withdrawal. In those cases, it
is not fully clear as to what extent coexisting (sub)clinical
symptomatology and self-triggered reactions cause the
patients social and emotional reactions to his/her tics.
Tics cause functional interference (e.g., impairment
of academic achievements)
Functional interference due to tics is relatively rare [87].
However, especially homework and falling asleep can be
prolonged by bouts of tics and sleep may be disturbed
followed by hypoarousal during daytime. Frequent phonic
tics can impair ﬂuency of speech and thus conversations.
Moreover, children can expend mental energy in the
classroom to suppress their tics, thus reducing their atten-
tion to schoolwork and interfering with their academic
performance [130].
Pharmacological treatment options for TS
Pharmacotherapy has probably the fastest onset when com-
pared with behavioral treatment options but this clinical
experience has never been tested in a clinical trial. The same
holds true for the efﬁcacy of tic reduction.
Genetic studies have so far not succeeded in pinpointing
a clear deviation in the biochemical pathways in patients
with TS. The existing models are mainly based on the
efﬁcacy of medication rather than on rigorous and repli-
cable models. Findings from clinical medication studies, as
well as from imaging studies and human material from
blood, urine, cerebrospinal ﬂuid, and postmortem brain
tissue analyses in rather small samples led to the common
hypotheses on neurochemical deviances in TS [97].
Although evidence is appealing for deviances in the dopa-
minergic system, other imbalances, such as in the
serotoninergic, noradrenergic, glutamatergic, Gamma-
aminobutyric acid (GABA)-ergic, cholinergic, and opioid
metabolism in TS [97, 267] seem probable. Moreover,
evidence grows that those systems play interactively
together, especially the dopaminergic [263] and the sero-
tonergic [160] system.
Studies supporting the strong hypothesis of an imbal-
ance in the dopaminergic system have shown an increased
number of striatal [285] and cortical [157, 290] dopamine
receptors, as well as differences in binding to dopamine
transporters in the basal ganglia [42, 233, 249, 286, 287]
and release of dopamine following stimulant application
[250]. Therefore, modulating the dopaminergic metabolism
(particularly by blocking the post-synaptic D2-receptors) is
the main action of drugs used in the pharmacologic treat-
ment of tics.
Given that only a limited number of studies on phar-
macological treatment options for TS met rigorous quality
criteria, we have devised a two-stage approach. First, we
present the highest level of evidence by reporting the
ﬁndings of existing Cochrane reviews in this ﬁeld. Subse-
quently, we provide the ﬁrst comprehensive overview of all
reports on pharmacological treatment options for TS
through a MEDLINE, PubMed, and EMBASE search for
all studies that document the effect of pharmacological
treatment of TS and other tic disorders between 1970 and
November 2010. We found additional studies by going
through references of each article. Given the scarcity of
well-designed and well-powered studies, we think it is
timely to provide such a complete overview of all available
studies in order to present all facets of pharmacologic
treatment accumulated over the past decades. Finally, we
present a summary of the current consensus on pharma-
cological treatment options for TS in Europe to guide the
clinician in daily practice. This summary is, however,
rather a status quo combined with a clinically helpful but
merely low evidence guideline and is mainly driven by
expert experience and opinion, since rigorous experimental
studies which would allow to better guide through well
based clinical evidence are scarce.
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and include all available studies in view of the small base
of evidence of pharmacological treatment options for TS.
We present all existing studies for the different pharma-
cological agents, with respect to their effects on tics and
other accompanying symptoms and adverse reactions or
interactions with other agents.
Cochrane reviews
Although broad clinical experience guides the pharmaco-
logic treatment of tics, the actual evidence based on ran-
domized controlled trials (RCT) is alarmingly limited.
Therefore, it is not surprising that all three existing
Cochrane reviews on the pharmacologic treatment of tics in
TS [51, 186, 189] came to the same conclusion, i.e., that
the evidence for efﬁcacy and safety of the studied drugs
does not allow ﬁrm recommendations.
Pringsheim et al. [189] included six randomized con-
trolled trials on pimozide in TS (total 162 participants, age
range 7–53 years). Pimozide was compared to placebo and
haloperidol (two trials), placebo (one trial), haloperidol
(one trial), and risperidone (two trials). In summary, the six
studies showed that pimozide was more effective than
placebo in reducing tics. It was slightly less effective than
haloperidol but showed fewer adverse reactions. The two
studies that compared pimozide and risperidone revealed
no important differences between these medicines for
either reduction of tics or adverse reactions.
A more recent Cochrane review searched for all ran-
domized, controlled, double-blind studies comparing atypi-
calantipsychoticswithplaceboforthetreatmentofticsinTS
[186]. However, it did not include the two above-mentioned
trials because both the studies compared the atypical agent,
risperidone, with an active treatment modality, without a
controlgroupthatreceivedplacebomedicine.Parallel-group
and crossover studies of children or adults, at any dose and
for any duration, were screened. Only three randomized
placebo-controlled trials, two involving risperidone and one
involving ziprasidone were thus identiﬁed. Risperidone was
superior to placebo in one trial although the 95% conﬁdence
intervals were large. Two trials did not detect a statistically
signiﬁcant difference between treatment with risperidone
and with ziprasidone against placebo. Risperidone caused
several extrapyramidal adverse reactions and weight gain.
The third Cochrane review on the pharmacological
treatment of TS [51] analyzed the effect of Delta 9-tetrahy-
drocannabinol(Delta9-THC).Atotalof28differentpatients
included in one double blind, crossover trial and in one
double blind, parallel group trial were studied. Although
both trials reported a positive effect of Delta 9-THC, the
improvements in tic frequency and severity were small and
only apparent on selected outcome measures.
In summary, all three available Cochrane reviews
urgently advocate for future trials with longer durations
and larger groups to investigate the safety and efﬁcacy of
pharmacological treatment in TS. Future trials should also
use the Yale Global Tic Severity Scale (YGTSS) as pri-
mary outcome measure and standardized rating scales of




Positive effects for D2 dopamine receptor blockers have
been reported in the treatment of tics since 40 years (in
average a marked decrease of tics in about 70% of cases
[237]). Particularly, the blockade of striatal D2 dopamine
receptors is thought to lead to reduction of tics. However, a
high blockade of the receptors correlates also with the rate
of unfavorable adverse reactions, such as extrapyramidal
symptoms (EPS) or tardive dyskinesia (TD) [27].
Typical antipsychotics For a long time, placebo-con-
trolled treatment studies in TS have been conducted only to
prove the efﬁcacy of the typical antipsychotics, haloperidol
and pimozide. In an early randomized, double-blind,
placebo-controlled crossover study, both pimozide and
haloperidol signiﬁcantly decreased tic frequency in nine
patients with TS [206]. The results of a subsequent ran-
domized, double-blind, placebo-controlled study of the
treatment of 57 patients with TS conﬁrmed that both hal-
operidol and pimozide were more effective than placebo,
but haloperidol was slightly more effective than pimozide.
Adverse reactions occurred more frequently with haloper-
idol versus placebo, but the frequency was not signiﬁcantly
different for haloperidol as compared with pimozide [236].
The dosages used in this study ranged from 2 to 20 mg/day
for haloperidol and from 2 to 48 mg/day for pimozide. The
effect of the medicine with a strong blockade of D2
dopamine receptors reduced tics in up to 80% of the cases
[236]. However, in daily clinical practice, lower doses such
as 1–4 mg/day for haloperidol and 2–8 mg/day for pimo-
zide are typically used nowadays to treat TS [128, 191,
224].
In a double-blind, 24-week, placebo-controlled, ran-
domized, double-crossover study of more commonly used
doses of haloperidol (mean of 3.5 mg/day) and pimozide
(mean of 3.4 mg/day) conducted with 22 subjects, aged
7–16 years, pimozide was signiﬁcantly more effective than
placebo in reducing tics, whereas haloperidol failed to have
a signiﬁcant effect. Moreover, haloperidol exhibited a
threefold higher frequency of serious adverse reactions and
signiﬁcantly greater extrapyramidal symptoms relative to
pimozide [214]. In contrast to several other studies,
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limited study power.
Furthermore, a long-term naturalistic follow-up study
(1–15 years) of 33 TS patients treated with pimozide
(2–18 mg) or haloperidol (2–15 mg) suggested beneﬁts of
pimozide over haloperidol; both drugs produced compa-
rable relief of symptoms at follow-up; signiﬁcantly, more
patients on haloperidol (8 of 17) as compared with those on
pimozide (1 of 13) discontinued treatment [218]. In addi-
tion, haloperidol produced signiﬁcantly more acute dyski-
nesia/dystonia than pimozide.
A third typical antipsychotic, ﬂuphenazine, has been
used particularly in the United States for many years to
treat TS, though it has merely been studied systematically.
In an open-label study that included both children and
adults, ﬂuphenazine was effective at doses ranging from 2
to 15 mg/day in 17 of 21 patients [91]. In a naturalistic
follow-up of 41 patients, treatment with ﬂuphenazine
for at least 1 year was safe and effective [240]. A small
controlled study of ﬂuphenazine, triﬂuoperazine, and
haloperidol found similar reduction of tics. However, ﬂu-
phenazine was better tolerated [25]; haloperidol was
associated with more sedation and extrapyramidal adverse
reactions.
The high frequency of drowsiness and extrapyramidal-
motoric adverse reactions (dystonia, akathisia, pseudo-
Parkinsonism, probably due to the strong dopaminergic
blockade in the nigrostriatal pathways) limits the use of the
typical antipsychotics foremost in higher doses. It has also
been reported that akathisia due to antipsychotic agents
may worsen the tic symptoms [280]. Moreover, several
case reports raised concerns about the risk of treatment
with typical antipsychotics to induce tardive dyskinesia
[93, 192, 241]. Although, it is difﬁcult to conﬁdently
quantify the rates of tardive dyskinesia owing to the limited
long-term data available, the risk of this potentially debil-
itating and treatment-persistent adverse reaction ought to
be considered in the choice of treatment [284]. This is
important with greater certainty as atypical antipsychotics
have shown a signiﬁcantly lower risk of tardive dyskinesia
[155].
Other adverse reactions, e.g., the onset of anxiety [29,
138, 154] or hyperprolactinemia with its adverse reactions,
such as gynecomastia, galactorrhea, irregular menses, and
sexual dysfunction [205] are more common adverse reac-
tions than tardive dyskinesia. Additionally, during long-
term medication with haloperidol, the increased appetite
may result in signiﬁcant weight gain [114].
Benzamides The benzamides (tiapride, sulpiride, and
amisulpride) are further selective D2 dopamine receptor
antagonists but in contrast to the typical antipsychotics
with low (sulpiride) or as good as no (tiapride) antipsy-
chotic action.
In addition to tiapride binding to the supersensitive D2
dopamine receptors in the ventral striatum and parts of the
limbic system (Locus coeruleus), a blockade of some
serotonergic receptors (5HT3, 5HT4) is assumed. Since the
1970s, there have been reports about successful treatment
of TS with tiapride [61, 124, 139, 145, 183]. Several pla-
cebo-controlled studies on small sample sizes followed
[43, 74]. Only one randomized, double-blind, placebo-
controlled crossover study has been published with tiapride
(involving 17 children), indicating a signiﬁcant reduction
of tic symptomatology [68]. The main adverse reactions
were drowsiness, moderate transient hyperprolactinemia,
and weight gain (the maximum was 10 kg during
18 months in two children). Such massive weight gain is
rather the exception than the rule, because the mean weight
gain was 2–4 kg [151] with the dosage range of
100–900 mg/day. Tiapride had no adverse reactions on
children’s cognitive performance. Neither neurophysio-
logical parameters such as the EEG frequency analysis and
sensory-evoked potentials were affected by tiapride nor
were the neurosecretory, hypothalamic-hypophyseal regu-
lation of the sex hormones, thyroid stimulating hormone,
growth hormone, or thyroid hormone impaired. This rather
advantageous proﬁle of short- and long-term adverse
reactions with doses effectively reducing tics has been
proven in rats too [23, 227].
Since 1970 [291], the positive effects on tics have also
been reported regularly for the benzamide sulpiride [199].
It is a highly selective D2-dopamine receptor antagonist
associated with less extrapyramidal and vegetative adverse
reactions than haloperidol [156]. An ongoing discussion
focuses on whether that medication possibly has a speciﬁc
binding in mesolimbic and mesocortical systems. In addi-
tion to its mild antipsychotic potency, it has some antide-
pressant effect in low doses (in particular 50–200 mg
daily) as well as a stimulating and anxiolytic effect [176].
In an open-label retrospective review in which 63 out of
114 patients (55%) suffering from TS had been treated with
sulpiride [197], worthwhile beneﬁcial effects occurred in
37 patients (59%). In a 14-week, randomized, double-blind,
placebo-controlled crossover study trial of ﬂuvoxamine (a
speciﬁc 5HT reuptake inhibitor) versus sulpiride followed
by single-blind combined therapy (4 weeks) in 11 subjects
with coexisting obsessive–compulsive disorder and TS
[85], sulpiride monotherapy reduced tics and non-signiﬁ-
cantly improved obsessive–compulsive symptoms. Flu-
voxamine, either alone or combined with sulpiride, non-
signiﬁcantly ameliorated tics and reduced obsessive–com-
pulsive symptoms. Just recently in an open-label study with
189 children and adolescents with an average age of
8 years (range 3–15 years), 6 weeks’ treatment with sul-
piride improved motor as well as vocal tics. The most
commonly encountered adverse reaction was sedation
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fering from OCD without tics, sulpiride has proven its
efﬁcacy [14, 270]. In one case of treating TS with the
combination of sulpiride and imipramine, the tics increased
[69]. This might be attributed most likely to the reported
effects of increase of serotonin associated with increase of
tics.
The main adverse reactions of sulpiride treatment are
sustained sedation or drowsiness (up to 25%) and, less
frequently, depression, despite its antidepressant, drive-
normalizing, and mood-brightening potential [197].
Patients have also complained about restlessness and sleep
disturbances [209]. Another important problem with sul-
piride is a strong stimulation of prolactin-secretion causing
galactorrhea/amenorrhea and a commonly observed
increased appetite leading to weight gain [12, 105, 281].
Other adverse reactions occur less frequently (hypotension,
rarely long-QT syndrome, dry mouth, sweating, nausea,
activation or sedation, insomnia, allergic rash, or pruritus).
There has only been one case report about tardive dyski-
nesia in an adult treated with sulpiride for tics (Eapen,
Katona et al. 1993).
Successful treatment of TS disorder with amisulpride
has been published only in case reports [75, 272].
Atypical antipsychotics Atypical antipsychotics are
effective in the treatment of TS too. The best evidence is
available for risperidone. We will herein review all atypical
antipsychotics in the order of their date of FDA approval
for non-TS disorders.
Clozapine, a dibenzodiazepine with 5-HT2A, 5-HT2C,
5-HT3, and weaker D1 antagonist properties, and the ﬁrst
FDA-approved atypical antipsychotic agent (FDA
approval: 1990), has not been found to be helpful in the
treatment of TS in several case reports which also docu-
mented the serious adverse reactions associated with this
agent [35]. On the contrary, it is reported that clozapine
exacerbates tics [13] and induces stuttering, facial tics, and
myoclonic seizures [15].
The atypical antipsychotic agent best studied for the
treatment of TS is risperidone (FDA approval: 1993) with
a high afﬁnity for dopamine D2- and 5-HT2-receptors.
However, in several case reports and open-label studies
including small groups of patients, risperidone showed
similar efﬁcacy across different ages as haloperidol and
pimozide did with less frequent and less severe adverse
reactions [30, 58, 86, 122, 140, 198, 219, 238, 261, 275].
The efﬁcacy of risperidone has been conﬁrmed in two
randomized, double-blind, placebo-controlled trials
involving 26 children and 8 adults with an age range
6–62 years [226], and 48 adolescents and adults between
14 and 49 years, [60], respectively, with mean daily doses
of about 2.5 mg (range 1–6 mg/day). Gaffney et al. sub-
sequently [83] compared 8 weeks’ treatment effects of
risperidone with clonidine in 21 subjects with TS aged 7 to
17 years in a randomized, double-blind study. Risperidone
and clonidine appeared equally effective in the treatment of
tics; however, in the cases with comorbid obsessive–com-
pulsive symptoms, risperidone was superior. The most
common adverse reaction seen with both treatments was
mild-to-moderate sedation, which subsequently resolved
with continued administration of the medication or with a
dose reduction. No clinically signiﬁcant extrapyramidal
symptoms were observed.
Furthermore, in a 12-week, randomized, double blind,
parallel group study, both risperidone (26 patients were
treated with a mean daily dose of 3.8 mg) and pimozide (24
patients were treated with a mean daily dose of 2.9 mg)
reduced tics, anxiety, and depressive mood [28], whereas
obsessive–compulsive symptoms improved only in the ris-
peridone group. The latter ﬁnding is in line with the superior
efﬁcacy of risperidone for coexisting obsessive–compulsive
symptoms in TS in the study of Gaffney et al. [83] as well as
in an earlier case report [86]. Although the severity of
extrapyramidaladversereactionswaslowinboththegroups,
fewer patients in the risperidone group reported extrapyra-
midal adverse reactions (n = 4) as compared with the pim-
ozide group (n = 8). Depression, fatigue, and somnolence
were reported as the most prominent adverse reactions in
both treatment groups. This is in line with a retrospective
studycarriedouton58adultandadolescentTSpatientswho
weretreatedwithrisperidone;17patients(29.3%)developed
a major depressive disorder, including 1 patient who later
committed suicide, and 13 patients (22.4%) became dys-
phoric while taking risperidone [143]. In a randomized,
double blind, crossover study of 19 TS children (ages,
7–17 years), who underwent a 4-week treatment with pim-
ozide or risperidone, followed by the alternative treatment
after a 2-week placebo washout, risperidone was more
effective than pimozide in reducing tics, in contrast to
Bruggeman et al.’s report [28], which suggested that ris-
peridone and pimozide were equally efﬁcacious in the
treatment of TS.28 Risperidone, however, was associated
with more weight gain during the 4-week treatment periods.
No serious adverse reactions were reported [88].
Risperidone also appears to be effective in treating
aggressive behavior in patients with TS. In a retrospective
chart review of 28 children and adolescents (one female)
aged 5–18 years with TS and aggression problems, 22
(78.5%) showed both decreased aggression scores and tic
reduction when treated with a mean daily dose of 2 mg
risperidone [219]. This is in accordance with the potential
of risperidone to manage pediatric aggression in other
disorders [177]. Moreover, positive effects of risperidone
not only on tics but also on sleep disturbances have been
reported in the case of a 12-year-old boy with no previous
psychopharmacological treatment [7].
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causality between treatment and the natural course of tic
symptomatology has also been mentioned for risperidone
leading to one report about induction of tics by risperidone
[72].
Several case reports [17, 18, 117, 141] and open-label
studies [33, 126, 148, 262] have suggested efﬁcacy of
olanzapine (FDA approval: 1996) in the treatment of TS in
adolescents and adults during the last 10–15 years. In four
patients with severe TS (aged 19–40 years), a 52-week,
double blind, crossover study with olanzapine (5 and
10 mg daily) versus low-dose pimozide (2 and 4 mg daily)
was performed [171]. The reduction in tic severity was
highly signiﬁcant with 10 mg olanzapine versus baseline
and versus 2 mg pimozide, and was signiﬁcant for 5 mg
olanzapine versus 4 mg pimozide. Only moderate sedation
was reported by one patient during olanzapine treatment,
whereas three patients complained of minor motor adverse
reactions and sedation during pimozide treatment. All
patients opted for olanzapine treatment at the end of the
study. Compared to other antipsychotics, olanzapine has a
greater activity at serotonin 5-HT2 receptors than at D2
dopamine receptors. This may explain the lack of extra-
pyramidal effects. Additionally, olanzapine does not
appear to block dopamine within the tubero-infundibular
tract, explaining the lower incidence of hyperprolactinemia
than with typical antipsychotic agents or risperidone.
Nevertheless, the most widely reported adverse reactions
were drowsiness/sedation and increased appetite frequently
followed by weight gain [148]. In this context also meta-
bolic adverse reactions (glucose and lipid metabolism)
arise [184], although there seems to be no correlation
between weight gain and metabolic disturbances [153].
Quetiapine (FDA approval: 1997) with its greater
afﬁnity for 5-HT2 receptors than for dopamine D2 recep-
tors has shown its efﬁcacy in reducing tics in two children
with TS [179, 181, 182]. In an open-label trial with 12
subjects with a mean age of 11.4 ±2.4 years quetiapine
reduced tics signiﬁcantly [159]. Three subjects complained
of sedation in the ﬁrst week of treatment, but in the
8 weeks under investigation patients did not experience
extrapyramidal adverse reactions and no statistically sig-
niﬁcant weight gain. Contrarily, in a retrospective study
with longer observation period and higher dosage (175.0
SD 116.8 mg/day) of quetiapine the only noteworthy
adverse reaction was weight increase. Quetiapine reduced
tics also signiﬁcantly in an open label study of 12 patients
aged 8–18 years with TS [48]. Routine laboratory param-
eters and serum prolactin level were all normal and did not
change throughout treatment.
Although therehas been greathopefor ziprasidone (FDA
approval: 2001) as a potent treatment option in TS without
theproblemofweightgain[6],onlyonerandomized,double
blind, placebo-controlled study in 28 children and adoles-
cents(7–17 years)[212]andoneopenopen-labelstudyin24
children and adolescents (7–16 years) so far has proved this




seen in clinical practice. This may be caused by enhanced
5-HT2C antagonistic activity of ziprasidone at low doses
[260]. No patient experienced extrapyramidal symptoms,
akathisia,ortardivedyskinesia,although administrationofa
single,lowdoseofziprasidonemaynotbereﬂectiveofeither
higher doses or long-term risk in a naturalistic treatment
setting [213]. In addition, there was no weight gain and
changes of the analyzed laboratory parameters except of
prolactin. Although QT prolongation has been discussed
prominently in ziprasidone, a single dose of ziprasidone to
treat TS was well tolerated without clinically signiﬁcant
effects on electrocardiograms collected around the time of
maximum serum concentration [213] and even in higher
doses no elevated risk of QT prolongation has been reported
compared to other antipsychotics [266].
In addition to ziprasidone also aripiprazole (FDA
approval: 2002) induced no weight gain during an 8-week,
open-label trial with a ﬂexible dosing strategy of aripip-
razole in 72 children and adolescents with TS aged
6–18 years [49]. In a 10 week open-label, ﬂexible-dose
study with eleven subjects (10 males) with TS (age
9–19 years) who had not responded to or had not tolerated
previous tic medication, effects of aripiprazole were
promising [142], albeit with some weight gain in ﬁve
patients. Finally, in an open-label, ﬂexible-dose study
including sixteen children (15 males) aged 8–17 years
there was a mean increase of 2.3 kg after a 6-week trial
with aripiprazole [167]. It provides a high afﬁnity at
dopamine D2 receptors but acts in contrast to other atypical
antipsychotics as a partial agonist. Under treatment of
clinical useful doses (10–30 mg/day) aripiprazole exhibits
D2-receptor binding of 80–100% [96]. However, while
binding at the active state of D2-receptors, aripiprazole
shows 30% agonistic activity compared to dopamine [34].
Aripiprazole also acts as a partial agonist at 5-HT1A
receptors and as a potent antagonist at 5-HT2A receptors
[113]. This proﬁle raised the hope that aripiprazole might
be superior to previous pharmacological treatment options
even in refractory cases. Excellent efﬁcacy in the treatment
of tics has been reported in a total of 201 cases, at least 31
of them adults [31, 47, 49, 52, 55, 63, 76, 103, 106, 118,
119, 142, 158, 166, 167, 173, 265, 288, 289]. A random-
ized, double blind, placebo-controlled study is, however,
still lacking. Nevertheless, this drug should be considered
because of its promising perspective based on actual clin-
ical experiences. Even in ‘‘refractory’’ TS, aripiprazole has
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28-year-old man [16] as well as good efﬁcacy in treating
TS and coexisting OCD in an adult female [283].
Accordingly, Budman et al. [32] found in their retrospec-
tive, observational study of 37 children and adolescents
with TS who were refractory to previous treatment that
aripiprazole still reduced tics as well as explosive outbursts
in these patients. Aripiprazole was tolerated reasonably
well, although 8/37 (22%) children discontinued treatment;
most common adverse reactions included weight gain,
akathisia, and sedation at a mean daily dose of 12.3 (SD
7.50) mg in the 29 subjects who completed the study. In a
12-week, open-label trial with ﬂexible dosing strategy
aripiprazole revealed a good tic reduction in 15 partici-
pants, aged 7–19 years. Nausea and sedation were the most
commonly reported adverse reactions that ameliorated in
all participants within 2 weeks, with the exception of 1
participant who had continuously complained of sedation,
but did not stop taking the drug [232]. The mean weight
gain during this study was negligible.
For the newest atypical antipsychotic paliperidone
(FDA approval: 2006) as well as for sertindole (not
approved by the FDA for use in the USA) no data on the
treatment of tics have been published.
Noradrenergic agents
In general, noradrenergic agents (clonidine, guanfacine,
and atomoxetine) are mostly used in children and adoles-
cents with a combination of attention-deﬁcit/hyperactivity
disorder (ADHD) and mild tics given their efﬁcacy in
treating ADHD symptoms in addition to tics [11]. Their tic-
suppressing effects seem to be generally smaller, however,
than those of antipsychotic agents.
Despite the frequent use of the a-2 adrenergic agonist
clonidine for nearly three decades in the treatment of TS,
controlled studies with clonidine are few in number. It is
used more commonly in America than in Europe [195].
Case reports of clonidine’s efﬁcacy in treating TS appeared
in the early 1980s [150] and open-label trial evidence has
been contradictory [45, 46, 234, 248]. A single-blind,
placebo-controlled trial demonstrated a signiﬁcant
improvement in 6 out of 13 patients [133]. A randomized,
placebo-controlled trial on 47 patients (7–48 years old)
suffering from TS showed that treatment with clonidine
reduced tic severity and frequency better than placebo
[134], whereas another randomized, placebo-controlled
study in 30 children and adults with TS found no difference
[92]. A randomized, double blind, placebo-controlled study
of desipramine and clonidine for the treatment of ADHD in
TS revealed that clonidine did not alter tic severity in 34
children aged 7–13 years [247]. However, in the largest
well-designed, randomized trial on orally administered
clonidine, which included a placebo group, clonidine
reduced tics signiﬁcantly [271].
A transdermal clonidine preparation is also available and
hasbeentestedfortheﬁrsttimeinninepatientsinaplacebo-
controlled crossover trial. Although no objective improve-
ment was recorded, most subjects felt they had improved
[84]. Arecentrandomized, double blind, placebo-controlled
multicentretrialusingaclonidineadhesivepatchrevealedin
the randomly assigned clonidine group (n = 326) a signiﬁ-
cant improvement of TS in 68.85% compared to 46.85% in
the clinical control group (n = 111) [62]. Accordingly,
clonidinetransdermalpatchtreatmentwaseffectivein53out
of 65 children with TS [116].
Adverse reactions of clonidine include sedation, dry
mouth, headache, irritability, and midsleep awakening
[62]. Blood pressure and pulse should be measured at
baseline and monitored during dose adjustment. Speciﬁc
guidelines for blood pressure monitoring during follow-up
have not been established but regular monitoring of pulse
and blood pressure changes, and symptoms suggestive of
cardiovascular problems (e.g., exercise intolerance, dizzi-
ness, syncope) is recommended [53]. Baseline and follow-
up electrocardiograms have been recommended in some
practice guidelines [64], but not in others [53]. Although
blood pressure is generally not a problem with clonidine,
patients and families should be educated about the possi-
bility of rebound hypertension, tics, and anxiety with
abrupt discontinuation [19]. Although many authors report
that the adverse reactions tend to be mild and transient, this
view is not fully supported by others [89, 99, 137] espe-
cially when moderate to severe tics require higher dosage.
Guanfacine, another a-2 adrenergic agonist, has modest
efﬁcacy in reducing tics and in improving attention in
children and adolescents. An open-label study of guanfa-
cine in 10 children with TS [40] and in 25 medication-free
children (23 males and 2 females) [24] with TS ? ADHD
aged 7–16 years revealed a signiﬁcant decrease in tic
severity and improvement in attention. In addition, a case
report had described a 6-year-old boy with TS treated
successfully with guanfacine [77]. These open label
observations were conﬁrmed by a randomized placebo-
controlled double-blind trial in 34 children with
TS ? ADHD with a mean age of 10.4 years [223]. In
contrast, in another double blind, placebo-controlled study
on 24 children with TS aged 6–16 years guanfacine was
not superior to placebo [50]. In summary, whether guan-
facine would be effective for the treatment of moderate to
severe tics remains unanswered [225]. In addition, the
suggestion that guanfacine is a better tolerated alternative
to clonidine remains unclear without a direct comparison
study [217].
The most common adverse reactions of guanfacine
are somnolence, headache, fatigue, sedation, dizziness,
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lence, sedation, and fatigue adverse reactions emerge
within the ﬁrst 2 weeks of dosing and generally remit
[210]. There is a concern that guanfacine has a propensity
to induce mania in children with a personal or family
history of bipolar disorder [102] as well as syncopal epi-
sodes probably due to drug-induced hypotension or bra-
dycardia [123]. Guanfacine approved to treat hypertension
in several European countries has been withdrawn from the
market in several European countries probably due to lack
of ﬁnancial success.
The selective noradrenaline reuptake inhibitor ato-
moxetine had already been shown to be effective in ran-
domized, placebo-controlled trials for treating ADHD in
children [41]. Also in the treatment of ADHD with
coexisting tics its efﬁcacy was tested in a large, industry-
sponsored multicenter study in 148 children [5]. Ato-
moxetine reduced both tics and ADHD symptoms in the
study’s subgroup suffering from ADHD ? TS [256]. Sig-
niﬁcant increases of mean pulse rate and rates of treatment-
emergent nausea, decreased appetite, and decreased body
weight were observed during medication with atomexetine.
Concerns were raised, however, that children with severe
ADHD or tics might have been unlikely to be enrolled in
the study [87] which had a fairly high dropout rate in both
treated (34%) and untreated (26%) groups during the
double-blind portion of the trial. Moreover, case studies
describe patients experiencing manifestation, recurrences,
or exacerbation of tics following treatment with atomoxe-
tine [136, 178, 180, 230].
Alternatives
Tetrabenazine, a vesicular monoamine transporter type 2
inhibitor, depletes presynaptic dopamine and serotonin
stores and blocks postsynaptic dopamine receptors. In view
of the hypothesized supersensitivity of dopaminergic
receptors thought to be responsible for the tics in TS [231],
tetrabenazine might be an alternative to antipsychotic
treatment. Its divergent mechanism of action might result
in different efﬁcacy and adverse reactions proﬁles than the
treatment with antipsychotics [109]. In some clinical
studies on hyperkinetic movement disorders, including
patients or samples with TS, tetrabenazine has shown its
potential to ameliorate tics [108, 109, 111, 112, 174, 268,
278]. Results of two retrospective chart reviews enrolling
only patients with TS (n = 77; mean age about 15 years;
[120] and [188]) showed that 18–24 months’ treatment
with tetrabenazine resulted in a moderate to marked
improvement in functioning and TS-related symptoms in
over 80% of patients. Adverse reactions included drowsi-
ness/fatigue (36.4%), nausea (10.4%), depression (9.1%),
insomnia (7.8%), and akathisia/parkinsonism (6.5%), but
these symptoms improved with reduction in dosage [120].
Weight gain was less pronounced in doses of comparable
efﬁcacy than under treatment with antipsychotics and most
patients who switched from an antipsychotic drug to tet-
rabenazine subsequently lost weight [170]. There were no
reports of tardive dystonia or serious adverse reactions. In
contrast there is a report about two patients with TS who
developed tardive dystonia after treatment with antipsy-
chotic agents. The dystonic movements persisted after the
offending drugs were stopped and improved with tetra-
benazine [252]. In summary, these ﬁndings encourage to
conduct further studies.
Findings from preclinical studies in animals have sug-
gested that nicotine might potentiate the effect of anti-
psychotic agents used to treat TS. Indeed, in 2 case reports
negative effects of smoking cessation on TS have been
reported [57, 59]. In initial open-label studies, chewing
nicotine gum in addition to treatment with antipsychotics
reduced tics in frequency and severity and improved con-
centration and attention [146, 216]. Similar effects were
observed in a subsequent controlled trial involving nicotine
gum plus haloperidol. Only in the group chewing the nic-
otine gum, tic frequency was reduced, while placebo gum
alone had no effect on tic symptoms [147]. However, the
short duration of effects as well as the bitter taste and
gastrointestinal adverse reactions limit the compliance.
Similar ﬁndings have been reported for application of
transdermal nicotine patches to potentiate haloperidol in
TS [242, 243]. In 11 poor-responders to antipsychotic
treatment of TS, transdermal nicotine patches delivering
7 mg of nicotine in 24 h reduced tics 47% in frequency and
34% in severity [244]. In two of these patients tic reduction
lasted even after removal of the transdermal nicotine pat-
ches. This result was in line with similar reports on tic
reduction longer than 4 weeks after 48 h of nicotine
administration by a transdermal patch [66, 67]. Corre-
spondingly, retrospective case studies also found that
application of a single transdermal nicotine patch deliver-
ing about 7 mg nicotine in 24 h resulted in a signiﬁcant tic
reduction for a mean of 10 days [239, 243]. The partici-
pants complained, however, about nausea and occasional
headache and sedation. In the ﬁrst randomized, double-
blind study 70 patients with TS were treated with either
transdermal nicotine (7 mg/24 h) or placebo patches in
addition to their individual optimal dose of haloperidol
[245]. In the patients who completed all 19 days of nicotine
(n = 27) or placebo (n = 29), improvement of emotional
and behavioral symptoms but also adverse reactions such
as nausea and vomiting were more frequent under nicotine
treatment. A subsequent randomized, double blind, pla-
cebo-controlled trial examined the acute (4 h) and sus-
tained (2 weeks) effects of a single dose of transdermal
nicotine on clinical (i.e., tics), attentional (continuous
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parental reports), and behavioral symptoms in 23 children
and adolescents with TS receiving treatment with anti-
psychotic agents. In the 14 evaluable patients with com-
plete primary efﬁcacy data, nicotine (compared to placebo)
failed to alter symptoms at 4 h but counteracted ERP-P300
signs of diminished attention seen 2 weeks following pla-
cebo treatment. Secondary efﬁcacy measures, including
patient self-reports and parental ratings, found nicotine to
reduce complex tics and improve behaviors related to
inattention [104]. One study investigated neurophysio-
logical mechanisms possibly underlying nicotine treatment
of TS by using transcranial magnetic stimulation (TMS). A
single dose of nicotine in 10 non-smoking and non-treated
adults with TS reduced tic severity as assessed by blind
video scoring in the majority of patients. In addition, nic-
otine abolished the reduced inhibition in patients compared
to controls [172].
Tetrahydrocannabinol (THC) has been suggested to be
effective and safe in the treatment of tics [162–164]
without inﬂuence on neuropsychological performance
[161]. This knowledge is based on a randomized, double
blind, placebo-controlled study in which 24 adult patients
with TS were treated over a 6-week period with up to
10 mg THC/day. No serious adverse reaction occurred and
the reported mild adverse reactions were dizziness, tired-
ness, and dry mouth. Hasan et al. [98] reported about a
15-year-old boy with treatment refractory TS plus ADHD
leading to severe physical and psychosocial impairment.
For the ﬁrst time after several years of unsuccessful med-
ication even with a combination of different agents, the
administration of THC improved tics considerably without
adverse reactions, allowing parallel stimulant treatment of
coexisting ADHD. Along with the THC treatment, TMS
measured cortical inhibition was increased.
In addition to the use of pharmacological treatment
options with systemic effects, there is increasing evidence
for the efﬁcacy of botulinum toxin injections to treat per-
sistent well-localized (non-complex) motor and, some-
times, vocal tics by temporarily weakening the associated
muscles. Initially, botulinum toxin injection was used for
selected severe cases [3, 107, 125, 229]. Other case reports
and case series followed also including children after the
age of 8 years [4, 131, 215, 257, 273, 279]. In 35 of 186
patients, botulinum toxin injections were effectively con-
trolling motor tics [8]. The effect on vocal tics was mini-
mal. Adverse reactions included temporary soreness and
mild muscle weakness. In 30 patients with vocal tics
assessment after 15 days and then 4 times over a 12-month
period botulinum toxin injection improved vocal tics in
93% of patients, with 50% being tic-free [187]. Mean
response time was 5.8 days and mean duration of response
was 102 days. Quality of life improved and premonitory
experiences dropped from 53 to 20%. Hypophonia was the
only adverse reaction of note (80% of patients). Just
recently, the positive short-term and long-term (up to
10 years) treatment effects of botulinum toxin injections
every 3 months on simple motor tics of 15 patients (mean
age 43 years; range 18–84) could be shown [190]. Marras
et al. [144] concluded from their randomized, double blind,
controlled clinical trial that the treated tic frequency as well
as the urge associated with the treated tic were reduced by
botulinum toxin injection. Still, the patients’ subjective
perception was that overall this treatment did not improve
their condition. This is perhaps due to the fact that only
selected subset of tics could be treated in each patient.
The dopamine autoagonist talipexole with putative
preferential activity on presynaptic dopamine receptors
was investigated one time in a randomized, double blind,
placebo-controlled study [90]. In 13 adult men with TS,
talipexole was poorly tolerated because of clinically sig-
niﬁcant sedation and dizziness. Tics did not improve at
tolerable doses. These ﬁndings suggest that talipexole has
no role in the regular management of tic disorders.
Clonazepam, a benzodiazepine which acts primarily on
the GABAergic system, has a long history in the treatment
of TS with dosages up to 6 mg/day [89]. Although there
have been no placebo-controlled trials in TS, open-label
studies have been carried out in adults [94, 274] and ado-
lescents with TS [115, 264]. In a single-blind comparison
with clonidine in 20 children, clonazepam was superior in
suppressing tics [61]. In a single-blind clinical study of 20
patients with TS, those with high red blood cell-to-plasma
choline ratios responded better to clonazepam than to
haloperidol [152]. As with all benzodiazepines, tolerance
and adverse reactions including sedation, short-term
memory problems, ataxia, and paradoxic disinhibition
often limit the use of clonazepam [89]. There are no data
on other benzodiazepines except a case report about the
therapeutic effect of low-dosage diazepam on facial tics in
children [78].
The GABA B receptor agonist baclofen, which is used
for the treatment of spasticity, has been examined in an
open-label study in a large cohort of children with TS [8].
250 of 264 patients on baclofen treatment experienced a
signiﬁcant decrease in the severity of tics. A small ran-
domized, double blind, placebo-controlled study of baclo-
fen in 10 children was inconclusive because there was a
reduction in overall impairment but no changes in tic fre-
quency or severity [251]. The results of these studies pro-
vide only modest support for the use of baclofen in TS.
Common adverse reactions were sedation and drowsiness.
Other GABAergic drugs including the anticonvulsant
levetiracetam have shown tic reduction in open studies on
TS [9, 71]. Adverse reactions, however, as well as the
ﬁnding that levetiracetam did not change the mean total
182 Eur Child Adolesc Psychiatry (2011) 20:173–196
123YGTSS and Clinical Global Impression score in a small
randomized, double blind, crossover study (n = 10) [99]a s
well as in a randomized, double blind, placebo-controlled,
crossover trial in 22 children with TS (mean age
12.2 years) [253] question its usefulness in the treatment of
TS.
Topiramate reduced tics in a small randomized, double-
blind study on 20 patients of a broad age range
(7–65 years) compared to placebo [110]. This is in line
with a chart review on 41 patients with TS [127] as well as
a previous report on two patients with TS who were suc-
cessfully treated with topiramate while previous medica-
tions were tapered and discontinued during the ﬁrst
2 weeks of treatment [1].
Lithium has been used successfully to reduce tics in ﬁve
of ten children and adolescents [121], a 22-year-old male
[277], and three adolescents suffering from TS who had
been initially treated with haloperidol [70]. Failure has also
been described, though [26], and ﬁrmer evidence is
lacking.
Several case reports [81, 220–222] and a randomized,
double-blind, placebo-controlled study involving 10 adults
with TS suggest that tic reduction may be achieved with
naloxone [129], an opioid receptor antagonist. Some
studies indicated that difference in response to naloxone in
TS subjects may be based on a dose–response effect [38,
276].
Some attention has also been given to the use of
treatments that include a modulation of the body’s
autoimmune-response. In children fulﬁlling criteria for
pediatric autoimmune neuropsychiatric disorders associ-
ated with streptococcal infections (PANDAS; a subgroup
of children with OCD and/or tic disorder that experience
symptom exacerbations following streptococcal infec-
tions), plasma exchange and intravenous immunoglobulin
(IVIG) were both effective in lessening of symptoms
[185, 293], although beneﬁts through IVIG could not be
conﬁrmed in unselected patients with a tic disorder
[101]. In a small prospective study, antibiotic prophy-
laxis with penicillin or azithromycin administered for
12 months in children fulﬁlling PANDAS criteria was
associated with signiﬁcant decreases in neuropsychiatric
exacerbations [254]. A case study of a patient with TS
reported beneﬁts of treatment with celecoxib, a COX-2
inhibitor [165].
Finally, a wide range of further neuroactive agents have
been examined non-systematically with divergent results
concerning their efﬁcacy in the treatment of TS. For
example buspirone [65], carbamazepine [168, 292], met-
oclopramide [2, 169], physostigmine [258, 259], and spir-
adoline mesylate [39] have received some attention. A
comprehensive overview of other case reports and non-
blinded trials can be found elsewhere [195].
Treatment of tics in the context of comorbidities
Children and adolescents with TS are frequently affected by
coexisting psychiatric conditions [79], which may be
regarded the rule rather than the exception. In clinical sam-
plesofTSabouthalfofthecasesalsomeetcriteriaforADHD
and vice versa, TS is present in about 20% of children with
ADHD[208,228].Thisco-occurrenceofTSandADHDisin
most cases associated with a higher psychopathological,
social,andacademicimpairmentresultingfromthenegative
impact of ADHD [10, 95, 200–202]. Besides, patients with
TS also suffer more frequently from obsessive–compulsive
symptoms or disorder (about 50%). Especially the need to
achieve a ‘‘just right’’ feeling in TS has to be seen as an
indicator for a continuum between TS and OCD [203].
Coexisting disorders cause often more clinical impair-
ment and may be more responsive to treatment than the
tics themselves [19]. It is therefore crucial to select an
appropriate treatment goal (tics or coexisting conditions),
when deciding on treatment options. Treatment of tics and
coexisting conditions should be prioritized according to the
impairment caused by each problem (for a decision tree see
Fig. 1). Thus, in many cases not the tics, but coexisting
problems require treatment e.g. ADHD or OCD. Clinicians
should thus avoid to start two medications simultaneously,
for instance one for tics and one for ADHD symptoms.
Primary treatment of a coexisting condition, such as
ADHD may reduce stress and improve attentional resour-
ces, and sometimes reduce tics by enhancing the individ-
ual’s ability of tic suppression.
Treatment algorithms of coexisting conditions in the
context of TS are similar to treatment of these conditions
without the presence of TS. Well-designed controlled clini-
cal trials have not indicated a deterioration of tics in persons
treated with stimulants [21] nor induction of ﬁrst tics by
stimulant treatment even in children at risk [175, 204].
Long-term treatment with methylphenidate (MPH) is not
associated with increases in tic severity. In a two year pro-
spective,openlabelstudyinwhicheffectsofMPHtreatment
were evaluated in 34 prepubertal children with ADHD and
with chronic multiple tic disorder, the authors found no
evidence that motor or vocal tics changed in frequency or
severity during the MPH maintenance therapy, whereas
initial behavioral improvements were maintained [82]. In a
subsequent blinded placebo-controlled discontinuation trial
in19childrenwithADHDandwithchronicticdisorderwho
had received psychostimulants for a minimum of one year,
tics did not change in their frequency or severity of motor or
vocal tics during the maintenance dose of stimulant medi-
cation comparedwith theplacebo condition.Treatmentwith
the maintenance dose was, however, associated with
behavioral improvement in ADHD symptoms, indicating
continued efﬁcacy. These studies prove that neither
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Tourette syndrome. Indications for treatment are given in ‘‘Tics cause
subjective discomfort (e.g. pain or injury)’’, ‘‘Tics cause sustained
socialproblemsforthepatient(e.g.socialisolationorbullying)’’, ‘‘Tics
cause social and emotional problems for the patient (e.g. reactive
depressive symptoms)’’ and ‘‘Tics cause functional interference (e.g.
impairment of academic achievements)’’. Solid arrow next level of
evaluation/treatment, dashed-dotted arrow monitoring after successful
treatment, dashed arrow alternating between two treatment options.
Note: patient preference (after psychoeducation) and availability of
therapists have to be considered in the choice of treatment. DBS deep
brain stimulation, THC Tetrahydrocannabinol
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patientswithticsleadtoanexacerbationoftics.Thus,abrupt
withdrawal of stimulant medication in children receiving
long-term maintenance therapy does not appear to result in
worsening of tic frequency or severity.
Higher doses of stimulants, in the range of 45 mg b.i.d.
of MPH and 22.5 mg b.i.d. of dexamphetamine, however,
may still lead to (reversible) tic exacerbations [36]. Thus,
in general, stimulants may be safely used in children with
TS and ADHD, when using doses based on the typical
clinical titration procedure [21]. Other treatment options
for ADHD in the context of TS include clonidine [271],
atomoxetine [5, 256], and desipramine [255].
Coexisting OCD in patients with TS may be less
responsive to serotonin reuptake inhibitor monotherapy
compared to OCD in patients without tics [149]. Co-
administration of an antipsychotic agent may be helpful
[20, 56].
Problems with clinical recommendations
for the pharmacological treatment of TS
Unfortunately, there has not been great improvement in
evidence concerning the pharmacological treatment of TS
since the overview of Robertson and Stern [199] who
stated that ‘‘the treatment of the Gilles de la Tourette
syndrome has evolved from case reports, clinical experi-
ence and more recently blinded trials usually in small
numbers of patients’’. Ideally, according to the principles
of evidence-based medicine to be recommended, an agent
must have shown its efﬁcacy in randomized, double-blind,
placebo-controlled studies. However, even today, evidence
for efﬁcacy of many agents that might be considered in the
pharmacological treatment of TS is often based on open
studies or randomized, double-blind, placebo-controlled
studies with quite small sample sizes [199]. Hence, there
exists only one drug which has been approved for TS
widely in Europe, which is haloperidol. However, because
of its adverse reactions it is nowadays usually a drug of
third line in clinical practice.
Particularly there is not a sufﬁcient number of ran-
domized, double-blind trials that have directly compared
different pharmacological treatment options of TS includ-
ing a placebo group [206, 214, 236]. Moreover, the het-
erogeneity of tic disorders with regard to the severity,
frequency, localization, complexity of the tics as well as
with regard to patterns of comorbidity demands further
investigation in terms of the identiﬁcation of factors that
may predict or moderate response to different psycho-
pharmacological agents [199]. Knowledge in this area
could help clinicians to reach a more tailored choice of
treatments. Currently, we have no data with regard to
response to a second medication in patients who did not
respond favorably to a ﬁrst line agent. That is, for example,
in patients who have not responded to risperidone, we do
not have scientiﬁc data from trials whether response may
be still expected from another antipsychotic, or rather from
a different type of medication. Finally, durations of exist-
ing studies have not always taken into account the natural
waxing and waning of tics (see Fig. 2). This calls for
longer observation periods and better rating instruments
than those of most existing studies. Investigations of long-
term efﬁcacy and adverse reactions are completely lacking.
Nevertheless, the treating physician should be aware of the
side effects proﬁle of the drug in question and initiate
adequate and suitable clinical and laboratory controls.
Moreover, studies comparing the effectiveness of
behavioral and pharmacological treatments in patients with
TS are absent. Thus, currently no scientiﬁc data are
available indicating whether behavioral treatment or med-
ication should generally be tried ﬁrst. An advantage of
behavioral treatments may be its better long term effects,
beyond the duration of the therapy, as well as their
assumed less frequent and less severe adverse reactions.
However, behavioral treatments require sufﬁcient motiva-
tion and certain ability for introspection, which may limit
its usefulness somewhat in younger patients (see also
Verdellen et al., this issue). Patients’ treatment preference
after thorough psychoeducation is an important aspect in
deciding between medication and behavioral therapy.
Deﬁnitely, pharmacologic treatment should be initiated
if behavioral treatment reveals insufﬁcient success. Con-
versely, drug-treated patients who do not experience suf-
ﬁcient tic reduction and/or suffer from non-tolerable
adverse reactions may be stimulated to (re-)start behavioral
interventions. In the rare cases of adults, who have extre-
mely impairing tics that are not sufﬁciently alleviated
through several pharmacological treatment options one




date 2 date 1
4
Fig. 2 Evaluation of treatment efﬁcacy in TS in light of natural
waxing and waning. At date 1 a therapeutic intervention could be
followed by tic reduction despite of its potential to increase tics or
without an effect on tics. This has to be ascribed not to causal
mechanisms of the intervention but to the natural waxing and waning
of the tics. Correspondingly, a therapeutic intervention at date 2 could
be followed by an increase of TS symptomatology despite its
potential to reduce tics. The therapeutic intervention might attenuate
the natural waxing of the tics. Conclusion: Meaningful appraisal of
treatment efﬁcacy in TS can only be given in most cases after longer
time
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123should consider deep brain stimulation (see Mueller-Vahl
et al., this issue).
Assessing response to treatment
The clinician should inform the patient and their parents
that the goal of a pharmacological treatment of TS is not to
completely eliminate the tics, but to achieve a reduction
aimed at eliminating the psychosocial impairment caused
by the tics. Unrealistic expectations on the efﬁcacy of
pharmacological treatment of TS will lead to frustration for
the child, family, and physician. Also, the desire to com-
pletely suppress tics can lead to overmedication and
adverse reactions that cause more problems than the tics
themselves. A common example of this is the overtreating
of children to the point of excessive daytime sedation or
unhealthy weight gain. Families should be informed that
medication typically only results in a 25 to 50% reduction
in tic symptoms.
Also, clinicians should always be aware of the natural
waxing and waning of tics in TS when evaluating effects of
treatments (see Fig. 2). It is advisable to consistently use
formal tic severity rating scales to more objectively assess
responses to treatment over time. Perhaps the most suitable
instrument is the YGTSS, a semi-structured interview
which records the number, frequency, intensity, complex-
ity, and interference of motor and vocal tics separately
[135]. But also the Tourette Syndrome Severity Scale
(TSSS) developed by Shapiro et al. [235], which is shorter
and more easy to use can be recommended.
What speciﬁc agents can be recommended?
As previously stated, there is a great scarcity of studies
directly comparing efﬁcacy and safety of different psy-
chopharmacological agents, foremost with regard to longer
term effects. Therefore every general recommendation
depends heavily on the experts’ own experiences and
preferences.
After reviewing the existing literature, it appears that the
best evidence arising from randomized, double-blind, pla-
cebo-controlled studies is still available for the typical
antipsychotics haloperidol and pimozide, with some indi-
cations that pimozide may be more effective and may have
a somewhat more favorable adverse reaction proﬁle than
haloperidol [189], with exception of its potential cardiac
effect. In clinical practice in Europe, however, over the last
years haloperidol and pimozide have been replaced step-
wise by atypical antipsychotics. Here, the best evidence is
undoubtedly available for risperidone [186, 189]. This is
also the agent that has been studied best. A lower risk for
adverse reactions compared to typical psychotics is
assumed in clinical use. Still many adverse reactions,
however, are similar to those associated with the use of
typical antipsychotics, including sedation, akathisia, weight
gain, extrapyramidal symptoms (EPS), neuromalignant
syndrome, and tardive dyskinesia. Although atypical anti-
psychotics generally are associated with a lower incidence
of EPS in youth [269], a rapid dose escalation is actually
associated with higher risk of EPS [37]. In addition, longer
experience with atypical antipsychotics reveals that new
risks need to be considered, such as metabolic syndromes
and QTc prolongation. The incidence of these risks in
patients suffering from TS, especially in children and
adolescents, cannot be easily predicted due to the paucity
of long-term studies in this population.
The choice of pharmacological treatments is not only
based on the efﬁcacy and the rate of adverse reactions but
also on the potential to show efﬁcacy in refractory cases. In
particular, aripiprazole is rather promising, given the lower
probability of weight gain as adverse reaction and prom-
ising effects in patients who had not responded to previous
treatments. Placebo-controlled studies with aripripazole are
still missing, however.
Availability of clinical experience with agents also plays
an important role in the choice of recommendable treat-
ments. In the German-speaking world the benzamides, such
as tiapride and sulpiride are commonly used as ﬁrst line
agents to treat TS particularly in children and adolescents.
Indeed, tiapride is regarded as the medication of ﬁrst
choice in the German guidelines for the treatment of tic
disorders without coexisting signiﬁcant emotional/obses-
sive–compulsive symptoms [207], Tiapride and sulpiride
are not available in the United States. This explains why
these agents are not mentioned in reviews from US authors
[87] and why their clinical efﬁcacy in TS as well as their
pharmacological properties have been underinvestigated in
comparison to other antipsychotic compounds. This small
base of evidence notwithstanding, Robertson and Stern
[199] conclude in their review that tiapride and sulpiride
are highly recommendable to treat TS in view of their
excellent balance of efﬁcacy and tolerability proven over
decades in clinical practice.
Further, severity of tics and presence of comorbidity
may affect choices of treatments. Although the evidence in
favor of the tic-suppressing effects of clonidine may be less
robust compared to the antipsychotics, clonidine may
actually improve ADHD symptoms alongside with sup-
pression of especially mild-to-moderate tics. In addition,
clonidine tends to alleviate initial insomnia and reduce
anxiety [217].
An important consideration, given the relative lack of
controlled clinical studies, is the opinion of experts.
Therefore, we sent by email a questionnaire to members of
the European Society for the Study of TS (ESSTS). All
clinicians with ample experience in the treatment of TS
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123were asked what psychopharmacological agent they would
consider ﬁrst, second, third, and subsequent choices in the
treatment of tics (provided there would be no contra-indi-
cation for any of the available agents, and there would be
no comorbidity). We received 22 responses out of the 60
members. We rated each ﬁrst choice agent with 4 points, a
second choice agent with 3 points, a third-choice agent
with 2 points, and additional agents with 1 point. As listed
in Table 1, most support from the experts has been pro-
vided for risperidone, with considerable support for cloni-
dine, aripiprazole, and pimozide as well (Table 2).
Based on the available evidence, experience with the
drug, and experts’ preference, risperidone can be recom-
mended as a ﬁrst choice agent for the treatment of tics.
Adverse reactions form the biggest limitation of risperi-
done, foremost so weight gain and sedation. Other drugs
merit recommendation as well. Relatively good evidence
with a better adverse reaction proﬁle than haloperidol is
available for pimozide. Tiapride and sulpiride can be rec-
ommended based on the broad clinical experience and
favorable adverse reaction proﬁle, although more con-
trolled clinical studies are required. Aripipazole has great
potential especially in treatment refractory cases and
probably less pronounced risk of severe weight gain.
Finally, clonidine can be given especially when coexisting
ADHD is present. All other agents mentioned in Table 1
may be considered as alternatives, once response to one or
more of the earlier mentioned medications has been
unsatisfactory.
In case of coexisting OCD, risperidone forms a good
ﬁrst choice also, based on the results of clinical trials. This
may be combined with a serotonin reuptake inhibitor.
Given the continuum of tics and obsessive–compulsive
symptoms, other agents recommended for the treatment of
tics may be tried as well; when partial response occurs,
addition of a serotonin reuptake inhibitor or of behavioral
treatment may be considered. Coexisting ADHD may be
treated with stimulants, atomoxetine, or clonidine. This
may be combined with an (antipsychotic) agent for the tics.
The current guidelines do not contain dosage recom-
mendations of each agent. In general, dosage should start
low and gradually increase with close monitoring of
response and adverse reactions. Most published studies
have included both children and adults, up to date, no
evidence suggests that the two age-groups should be trea-
ted in different ways apart from drug dosages [73, 199].
There are several hints that dosage of pharmacotherapy of
TS is not different between children, adolescents, and
adults once body weight has been taken into account [213,
282], but clear data are lacking. A commonly unrecognized
problem is the miss of adapting the dosage to the increasing
body weight during maturation.
To the best of our knowledge, only one drug is formally
licensed for the indication tics or TS in most European
countries: haloperidol. With all other medications (actual
exceptions of a certain country cannot be excluded), pre-
scription is on an off-label base, reﬂecting the paucity of
efﬁcacy and safety data, which would not be sufﬁcient for
approval by a registration authority for any of the men-
tioned agents. This should always be discussed with fam-
ilies prior to initiation of treatment.
The proposed principles of practice are considered as
guidelines only. We hope that this guideline may contrib-
ute to an improvement in the pharmacological management
of patients with tic disorders. The individual treatment of a
patient should be planned by considering the available
diagnostic information, the level of impairment associated
with tics, the efﬁcacy data and adverse reactions of treat-
ment options as well as patient’s preference to gain the best
result and adherence possible.
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